ASCO 2023 | OS results of the PRECIOUS trial: pertuzumab retreatment in HER+ LA/MBC

Yutaka Yamamoto, MD, PhD, Kumamoto University Hospital, Kumamoto, Japan, discusses findings from the Phase III PRECIOUS trial (NCT02514681) of pertuzumab retreatment in patients with HER+ locally advanced/metastatic breast cancer (LA/MBC). 219 patients were randomly assigned to receive trastuzumab and chemotherapy based on physician’s choice with or without pertuzumab retreatment. Overall survival was superior in patients who received pertuzumab, and no new safety signals were observed. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.